Skip to main content Back to Top
Advertisement

7/31/2019

Hypromellose Ophthalmic Solution

Products Affected - Description

    • Gonak, Akorn, 2.5%, 15 mL NDC 17478-0064-12
    • Goniosoft, OCuSOFT, 2.5%, 15 mL NDC 54799-0503-15
    • Goniotaire, Altaire, 2.5%, 15 mL NDC 59390-0182-13
    • Goniovisc, Hub Pharmaceuticals, 2.5%, 15 mL NDC 17238-0610-15

Reason for the Shortage

    • Akorn has hypromellose ophthalmic solution on shortage due to lack of raw materials.1
    • HUB Pharmaceuticals has hypromellose ophthalmic solution on long-term back order and did not provide a reason.2
    • Altaire did not provide a reason for the shortage.[3]
    • OcuSoft did not provide a reason for the shortage.[4]

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Akorn has Gonak 2.5% ophthalmic solution 15 mL bottles on allocation.1
    • HUB Pharmaceuticals has Goniovisc 2.5% ophthalmic solution 15 mL bottles on long-term back order and the company cannot estimate a release date.2
    • Altaire has Goniotaire 2.5% ophthalmic solution 15 mL bottles on back order and the company cannot estimate a release date.[3]
    • OCuSOFT has Goniosoft 2.5% ophthalmic solution on back order and the company cannot estimate a release date.4

Alternative Agents & Management

    • Hypromellose-containing products are used in ocular examinations and to treat dry eye.[5] There are products available ranging from hypromellose 0.2% to 2.5%.[5] The American Academy of Ophthalmology does not recommend a specific product over another.[6] Use products without preservatives if applying more than 4 times daily.[6]

References

    1. Akorn (personal communication). June 8, July 13, September 7, October 25, December 13 and 26, 2018; March 1, May 8, and July 29, 2019.
    2. HUB Pharmaceuticals (personal communication). June 8, July 11, September 5, October 25, December 13, 2018; May 8 and July 29, 2019.
    3. Altaire Pharmaceuticals (personal communication). June 8, July 11, September 5, October 25, December 13, 2018; and May 8 and 22, 2019.
    4. Ocusoft/Cynacon (personal communication). June 8, July 11, September 5, October 25, December 13, 2018; May 8 and July 29, 2019.
    5. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc; 2018.
    6. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Patern Guidelines. Dry Eye Syndrome. American Academy of Ophthalmology website. www.aao.org/ppp. 2013. Accessed June 11, 2018.

Updated

Updated July 31, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. Created June 8, 2018 by Anthony Trovato, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins